GSEP
IMDX

Golden State Equity Partners’s Insight Molecular Diagnostics IMDX Stock Holding History

Golden State Equity Partners’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-450
Closed -$1.48K – 1279
2026
Q1 		$1.48K Buy
+450
New +$2.61K ﹤0.01% 1716

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Golden State Equity Partners's IMDX Position: Q2 2026 in Review

Golden State Equity Partners sold out of Insight Molecular Diagnostics (IMDX) in Q2 2026, closing a stake of 450 shares — an estimated $1.48K sold.

Golden State Equity Partners first reported a position in IMDX in Q1 2026 and held it in 1 quarter. The position peaked at $1.48K in Q1 2026. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Golden State Equity Partners reported no remaining Insight Molecular Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 450 Insight Molecular Diagnostics shares in Q2 2026, an estimated $1.48K.
  • Golden State Equity Partners first reported a position in Insight Molecular Diagnostics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Insight Molecular Diagnostics position peaked at $1.48K in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.